Combination of MEK Inhibitor Binimetinib and CDK4/6 Inhibitor Palbociclib in KRAS and NRAS Mutant Metastatic Colorectal Cancers
Latest Information Update: 26 Aug 2024
At a glance
- Drugs Binimetinib (Primary) ; Palbociclib (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
Most Recent Events
- 22 Aug 2024 Status changed from active, no longer recruiting to completed.
- 10 May 2023 Planned End Date changed from 1 Apr 2023 to 3 Apr 2024.
- 06 Dec 2022 Planned End Date changed from 8 Oct 2022 to 1 Apr 2023.